18 studies on Kpv curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Bottom line: TitrateLab currently tracks 1,545 published third-party lab tests of Kpv across 666 identified manufacturers. Among reports with a positive numeric purity result, the average is 99.57%. Within this published corpus, 0 positive purity results were below 90%, and 56 reports showed measured quantity more than 10% below the label claim. These are batch-level observations, not guarantees of product identity, safety, or vendor quality.
As of 2026-09-03, vendor-blind retail asking-price averages for the US delivery market, calculated from the same in-stock exact-strength cells as the Peptide Price Index. Shipping is excluded.
| Strength | Average / vial | Observed range / vial | Average / mg | Coverage |
|---|---|---|---|---|
| 10 mg | $9.60 | $8.50–$10.50 | $0.96 | 5 sources · 5 offers |
| 30 mg | $22.75 | $19.50–$26.00 | $0.76 | 2 sources · 2 offers |
Asking prices are not manufacturing cost and do not establish product equivalence, quality, safety, or legality. The refresh date is the catalog build date; individual source observation dates are not available in this snapshot. View full price methodology →
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
Within that total, 401 batches have unresolved manufacturer identity. They remain in corpus-level lab evidence and are excluded from named-manufacturer rankings.
Eligible vendors have at least 2 deduplicated tests and 2 classifiable identity observations. Rank uses the 95% lower confidence bound on clean identity results; mean positive purity and test count break ties. Missing measurements are not passes. Exact-zero/not-detected and explicit wrong-compound markers count once per adverse certificate. This describes tested batches, not every product or shipment, and is not an endorsement.
| Rank | Manufacturer | Tests | Avg positive purity | Identity adverse results | |
|---|---|---|---|---|---|
| #1 | 36 | 99.5% | 0 of 28 (0.0%) 0 0% / not detected · 0 wrong compound · 8 unclassified | Reveal with Pro → | |
| #2 | 23 | 99.61% | 0 of 18 (0.0%) 0 0% / not detected · 0 wrong compound · 5 unclassified | Reveal with Pro → | |
| #3 | 16 | 99.32% | 0 of 14 (0.0%) 0 0% / not detected · 0 wrong compound · 2 unclassified | Reveal with Pro → |
Manufacturer identities are included with Pro. Batch counts and lab measurements remain visible.
Recent certificates: #101091 (99.42%) · #100546 (99.64%) · #100811 (99.48%) · #101096 (99.61%) · #101196 (99.82%) · #101456 (99.91%)
These findings highlight the significant potential of alpha-MSH peptides, particularly potent analogs like NDP-MSH, as a novel class of antimicrobial agents with a dual mechanism of action: direct bacterial killing an…
This research highlights the significant potential of alpha-MSH peptides as novel therapeutic agents for HIV-1 infection, particularly given their ability to modulate inflammation and directly suppress viral activity.…
This comprehensive synthesis underscores the significant therapeutic potential of alpha-MSH and its analogues for treating a wide array of inflammatory and autoimmune diseases, including conditions like psoriasis, rhe…
This research significantly advances our understanding of how alpha-MSH, KPV, and ACTH interact with human keratinocytes at a molecular level. Unraveling these specific signaling pathways provides a critical foundatio…
This research identifies [Ac-CKPV]2 as a highly promising candidate for the development of new therapies for fungal infections, particularly those caused by drug-resistant Candida strains which are difficult to treat.…
This review underscores the significant therapeutic potential of alpha-MSH related peptides as a novel class of drugs for treating chronic inflammatory and autoimmune diseases. Their multifaceted mechanism of action, …
This research highlights KPV as a promising therapeutic agent for intestinal inflammatory diseases due to its ability to be actively absorbed and exert potent anti-inflammatory effects. Its dual action of suppressing …
This study provides compelling evidence that the melanocortin-derived tripeptide KPV possesses significant anti-inflammatory and tissue-protective properties in preclinical models of IBD. Its ability to reduce multipl…
This research significantly broadens our understanding of α-MSH's complex anti-inflammatory mechanisms, indicating that its therapeutic potential extends beyond the well-characterized pharmacophore and melanocortin re…
This study reveals a novel immunomodulatory role for α-MSH in directly suppressing basophil activity, a critical component of allergic and inflammatory diseases. The significant reduction in histamine and leukotriene …
This research highlights PepT1 as a critical driver in the pathogenesis of colitis-associated cancer, suggesting it could be a novel diagnostic biomarker and a promising therapeutic target. The significant anti-tumor …
This study presents a highly promising and effective targeted oral delivery system for KPV, a potent anti-inflammatory tripeptide, directly to the inflamed colon. The innovative use of hyaluronic acid-functionalized n…
This research introduces a promising new method for modifying peptides to enhance their stability, which could significantly extend their half-life in the body and reduce the required dosing frequency for therapeutic …
This study highlights the significant potential of advanced drug delivery systems to substantially enhance the therapeutic efficacy of existing peptides like KPV for chronic inflammatory conditions. By improving both …
This study presents a highly promising and innovative therapeutic strategy for Ulcerative Colitis by directly targeting mucosal barrier dysfunction. The temperature-sensitive nature of the hydrogel allows for easy adm…
This comprehensive review highlights the significant therapeutic potential of tripeptides as a novel class of agents for treating chronic wounds and skin injuries. Their multi-faceted mechanisms of action, including a…
Free, no account — handy when you're working with Kpv.
Pro members save studies and unlock the full evidence breakdown and vendor lab data.
Buyer protection: Wrong or defective product? Report it within 7 days. We broker a refund or reship with the vendor.
$12 monthly or $33 lifetime
Create free account